NovoCure Surpasses Q1 Expectations
NovoCure posted stronger-than-expected Q1 2025 results, driven by revenue and GAAP earnings surpassing estimates.
NovoCure (NASDAQ:NVCR), a leader in oncology treatments using Tumor Treating Fields (TTFields) therapy, released its first-quarter results on April 24, 2025. The company reported notable gains with revenue rising to $155 million (GAAP) in Q1 2025, surpassing Wall Street’s estimate of $146 million.
GAAP earnings per share (EPS) were a negative $0.31, beating expectations of a negative $0.46 per share. The quarter was marked by robust patient growth and progress in clinical trials, though challenges in gross margins remain.
Source: Analyst estimates for the quarter provided by FactSet.
![How to Find Low-Competition Keywords with Semrush [Super Easy]](https://static.semrush.com/blog/uploads/media/73/62/7362f16fb9e460b6d58ccc09b4a048b6/how-to-find-low-competition-keywords-sm.png)
